Nutriflex Omega Peri infusionsvæske, emulsion Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

nutriflex omega peri infusionsvæske, emulsion

b. braun melsungen ag - alanin, arginin, asparaginsyre, calciumchloriddihydrat, glucosemonohydrat, glutaminsyre, glycin, histidinhydrochloridmonohydrat, isoleucin, kaliumacetat, leucin, lysinhydrochlorid, magnesiumacetattetrahydrat, methionin, natriumacetattrihydrat, natriumchlorid, natriumdihydrogenphosphat dihydrat, natriumhydroxid, omega-3-syretriglycerider, phenylalanin, prolin, serin, soyaolie, threonin, triglycerider, middelkædelængde, tryptophan, valin, zinkacetatdihydrat - infusionsvæske, emulsion

Zejula Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

zejula

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastiske midler - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Tecovirimat SIGA Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

tecovirimat siga

siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - antivirale midler til systemisk anvendelse - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 og 5. tecovirimat siga should be used in accordance with official recommendations.